Trametinib Kinase Inhibitor Kutsata BRAF V600 Mutation-Positive Cancers

Mtengo wolozera: USD 8-15/g

Dzina lazogulitsa Trametinib
CAS No. 871700-17-3
MF C26H23FIN5O4
MW 615.402623
Kuchulukana 1.743
Malo osungunuka 293-303 ° C

Lumikizanani nafe

tsatanetsatane wazinthu

Kufotokozera Mwatsatanetsatane

Trametinib ndi choletsa champhamvu komanso chosankha kinase chomwe chimagwiritsidwa ntchito makamaka pochiza melanoma yosasinthika kapena metastatic ndi kusintha kwa BRAF V600, komanso mitundu ina ya khansa yapamwamba kapena ya metastatic yomwe si yaing'ono ya m'mapapo. Nkhaniyi ikuwunika momwe amagwirira ntchito, zisonyezo zachipatala, komanso maubwino a trametinib pochiza khansa ya BRAF V600 mutation-positive.

I. Kumvetsetsa Trametinib:

A. Oral, amphamvu, ndi selective kinase inhibitor

B. Ndi wa gulu la MEK inhibitors

C. Imalepheretsa zochita za MEK1 ndi MEK2

D. Imalepheretsa kutsika kwa ERK1 ndi ERK2 kuwonetsa

II. Zizindikiro Zachipatala:

A. Mosasinthika kapena metastatic melanoma yokhala ndi masinthidwe a BRAF V600:

Chithandizo chophatikiza ndi dabrafenib mesylate

B. Postoperative adjuvant therapy ya BRAF V600 mutation-positive melanoma:

Chithandizo cha adjuvant ndi dabrafenib mesylate pambuyo pochotsa kwathunthu

III. Udindo mu Khansa Yosakhala Yaing'ono Yamapapo:

A. Khansara ya m'mapapo yosakhala yaying'ono ndiyomwe imayambitsa kudwala komanso kufa

B. BRAF gene mutation rate ndi kufalikira kwa kusintha kwa BRAF V600E

C. Trametinib's inhibitory effect pa BRAF V600 mutation-positive melanoma cell

IV. Njira Yochitira:

A. Kulepheretsa kosinthika kwa mitogen-activated extracellular signal-regulated kinase (MEK) 1 ndi MEK2

B. Zokhudza njira ya MAPK ndi mapuloteni a MEK

C. Kuletsa kuchuluka kwa maselo ndi njira ya ERK yotsika

V. Postoperative Adjuvant Therapy:

A. Ubwino wa mankhwala ophatikizika omwe amawunikira ndi Dabrafenib ndi Trametinib

B. Kupulumuka kwanthawi yayitali, kokhazikika kosabwerezabwereza (RFS) kumapindulitsa pamlingo wowopsa wa III BRAF mutation-positive melanoma odwala.

Trametinib, choletsa cha kinase inhibitor, imawonetsa kuthandizira kwambiri pochiza khansa ya BRAF V600 mutation-positive, makamaka yosasinthika kapena metastatic melanoma ndi mitundu ina ya khansa ya m'mapapo yomwe si yaying'ono. Kachitidwe kake kachitidwe, kuletsa MEK1 ndi MEK2 kinase ntchito, kumabweretsa kutsika kwa ERK njira yoletsa ndikuletsa kuchuluka kwa maselo. Trametinib, kuphatikiza ndi dabrafenib mesylate, imapereka chithandizo chamankhwala pamakonzedwe apamwamba komanso adjuvant kwa odwala BRAF V600 mutation-positive melanoma.
Lumikizanani nafe kuti mupeze malangizo amankhwala komanso zambiri zamitengo kuti mulimbikitse chisamaliro cha odwala.